TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast...
Hence then, the article about eirgenix signed the commercial licensinse agreement for it s second her2 biosimilar asset eg1206a was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A )
Also on site :
- Amazon’s ‘Breathable’ Athletic Skort Is a Tenniscore Staple That’s Perfect for Sports, Travel, and Errands
- Global Wellness Summit Announces Speakers and Topics--Including the Latest in Longevity Medicine, Women's Health, Wellness Travel and Neuroaesthetics
- Capri Pants Are on Trend for 2026 — Snag a Quick-Drying Cargo Pair That's ‘Perfect for Summer’ at Walmart